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The Expression of Ecotropic Virus Integration Site-1 in Seven Cancer Cell Lines
Abstract
The ecotropic virus integration site-1 (EVI1) gene is a transcriptional repressor implicated
in the control of cell proliferation and frequently over-expressed in cancerous cells. I investigated
the expression of this gene across seven cancer cell lines of varying morphologies. The tested
lines included leukemia lines Kasumi-3, U937, MOLT-4, and CEM, breast cancer line MCF7,
colorectal cancer line HT-29, and glioblastoma line M059K. Kasumi-3 and HT-29 are
documented to have high EVI1 expression. Protein concentrations were normalized with respect
to actin using SDS-PAGE and Western blotting. Western blots for EVI1 showed expression of
an unidentified protein with a molecular weight of 50-53kD in all lines except for Kasumi-3,
which had no detectable protein expression. The intensities of these bands were measured and
normalized with scaling factors determined from the Western blot for actin. The expression of
EVI1 may be below the detection threshold of this blotting system, making visualization of the
protein difficult.
Focusing Question
Initial Question: Is over-expression of EVI1 a common trait in cancerous cell lines?
Final Question: How does expression of EVI1 vary among cancerous cell lines of different
morphologies?
Rationale: Due to the lack of a true standard for over-expression, the experiment naturally tended
toward comparing levels of expression rather than determining over- or under- expression.
Additionally, the final focusing question reflects the complex nature of experimentation more
accurately than the simplistic yes/no initial question.
Introduction
The process of cellular growth and replication is called the cell cycle. Proper
development relies upon a complex system of checks and balances to prepare the cell before
division and prevent unwanted growth. Cancer is characterized by out-of-control duplication of
underdeveloped cells which lack these regulation mechanisms. Abnormal expression or mutation
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of proteins leaves the cell incapable of arresting the cycle (American Cancer Society [ACS],
2010), and accumulation of these deleterious mutations can result in malignant growth. One third
of women and one half of men in the United States will eventually develop cancer (ACS, 2010).
Current research focuses on finding mutations and other traits unique to cancer cells to provide
specific targets for treatment (ACS, 2009).
The ecotropic virus integration site-1 gene (EVI1) is found at the 3q26 locus (Liu, Chen,
Ko, Fields, & Thompson, 2006) and expressed at very low levels in normal tissue (Soderholm,
Kobayashi, Mathieu, Rowley & Nucifora, 1997). It is a transcriptional regulator with two DNAbinding zinc finger domains (Kurokawa et al., 1998). Studies have shown that EVI1 interferes
with the action of TGFβ, a transcriptional activator that signals growth arrest and initiates
apoptosis. TGFβ activates Smad3, which signals the transcription of necessary genes (Liu et al.
2006; Kurokawa et al. 1998). Liu et al. showed that EVI1 suppresses TGFβ-mediated initiation
of apoptosis through the recruiting of co-repressors to convert Smad3 from an activator to a
repressor. In addition, EVI1 activates the anti-apoptotic pathway PI3K/AKT, which also
interferes with TGFβ signaling by sequestering Smad3 (Liu et al. 2006; Conery et al., 2004).
Through these mechanisms, EVI1 encourages cell proliferation, interferes with differentiation
(Morishita, Parganas, Matsugi, & Ihle, 1992; Goyama & Kurokawa 2010), and confers resistance
to some chemotherapy drugs (Liu et al., 2006).
EVI1 was first discovered in induced myeloid leukemia in mice (Nucifora, 1997). It has
been established as a contributing factor in several cancers, including human myeloid leukemia
(Langabeer et al., 2006), colon cancer (Liu et al., 2006) and ovarian cancer (Brooks et al., 1996).
It has been linked to pathogenesis and poor patient prognosis (Goyama & Kurokawa, 2010), and
to chemotherapy resistance in tumor cells (Liu et al., 2006). Other studies have shown that
elevated expression of the isoform MDS1/EVI1 (MECOM) and expression of the fusion gene
AML1/MDS1/EVI1 contribute to the generation of acute myeloid leukemia (AML) and poor
patient prognosis (Senyuk et al., 2002).
The expression level of a gene in a sample can be determined by the amount of its protein
product that is detected. Sodium dodecyl sulfate- polyacrylamide gel electrophoresis (SDSPAGE) is a one-dimensional method of separating proteins based on molecular weight
(Scheppler, Cassin, & Gambuer, 2000). To find the expression level of the EVI1 protein, I used
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Western blots. A Western blot uses antibodies to detect a specific protein and quantify its
expression level (Scheppler et al., 2000). The expression of the protein can be compared among
several samples based on the intensity of the florescent bands (Scheppler et al., 2000). In order
for these comparisons to be valid, the protein concentrations must be normalized with respect to
a protein with confirmed, consistent expression in all samples. Once the same amount of this
protein is detected in each sample, differences in band intensity for the target protein can be used
to generate conclusions about gene and protein expression. I normalized with respect to actin,
which is ubiquitously expressed in eukaryotic cells (Uniprot, 2011a).
I examined seven cancer cell lines to see if the over-expression of EVI1 is a widespread
trait among different types of cancer or specific to a certain type. The cell lines were obtained
from ATCC and are displayed in Table 1. Of these lines, Kasumi-3 and HT-29 have
characteristically high EVI1 expression (ATCC, 2010). Based on previous findings and the
known anti-apoptotic effect of EVI1, I hypothesized that all seven lines would display consistent,
high levels of expression.
Materials and Methods
Cell Preparation: I cultured the seven cell lines in RPMI base media with fetal calf
serum (FCS) and standard 1% penicillin streptomycin and 1% glutamine. Kasumi-3 required
20% FCS; all of the other cell lines grew well in 10%. I harvested the cell lines after two months
of continuous growth and subculturing.
I determined cell viability for the suspended cell lines using a hemacytometer. Samples
were diluted 1:1 with trypan blue to distinguish live and dead cells and counted to determine
viability. I estimated adherent cell line viability by percent of the visible field adherent and
percent of visible surface covered. MOLT-4, U937, CEM, and Kasumi-3 are suspended cell
lines; M059K, MCF7, and HT-29 are adherent cells. Cell lines were harvested at >90%
viability to ensure sufficient protein expression. After harvesting, the cells were frozen, and the
cell lysate samples were prepared using a 1:1 ratio of phosphate-buffered saline with Tween
(PBS-T) and Laemmli buffer. For all gels and Western blots, I used a 10% acrylamide gel.
Protein Detection: I used SDS-PAGE as a preliminary test to confirm the presence of
protein in the samples. Using a standard volume for all cell lines, I performed a Western blot for
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actin (β-actin mouse monoclonal primary antibody, sc-47778, Santa Cruz Biotechnology) and a
series of Western blots for EVI1 (rabbit polyclonal primary antibody, ab28457, Abcam). I
developed the blots using chemiluminescent techniques. The blots were incubated with a
secondary antibody containing conjugated horseradish peroxidase, and developed using
SuperSignal® West Dura Extended Duration Substrate (Thermo Scientific). The horseradish
peroxidase degrades the lumminol b in the developer, producing florescent bands. The blots were
developed 1-3 minutes before photographing.
I determined the scaling factors for normalization from the actin blot using Gel Pro
Analyzer. EVI1 blots were incubated with primary antibody overnight and with secondary
antibody for two hours to compensate for the low constitutive expression. The intensities of these
bands were also measured with Gel Pro Analyzer and normalized using the scaling factors from
the actin blot. U937 was not used in this phase of testing.
Results
All lines were at

94% viability at harvesting, and all lines except Kasumi-3 had total

cell counts of at least 71,000 (Table 2).
The Western blot for actin using 5uL of each cell line showed unequal actin expression
(Figure 1). The scaling factors determined for normalization determined from this blot are
displayed in Table 3. Kasumi-3 showed no protein expression, so it was not considered. The final
EVI1 blot (Figure 2), was run with a standard concentration of 20uL. The protein shown is
between 50 and 53kD and appears in all considered cell lines. The scaled intensities of this band
for each cell line are displayed in Table 4. The highest expression of this protein was seen CEM
and HT29, while the other cell lines showed similar, lower expression.
Conclusion
The results contradict my hypothesis and show no conclusive expression of EVI1. The
final result, showing a protein of 50-53kD, does not match any known isoform of EVI1 (Uniprot,
2011b). Because of the low constitutive expression (Soderholm et al., 1997), the EVI1 signal
may have fallen below the detection threshold of this blotting system.

4

Wendy Bindeman

3 May 2011

Discussion
Six isoforms of EVI1 have been documented, ranging in size from 117kD to 140kD.
Other sources have evidence of isoforms with molecular masses of 88kD (Goyama & Kurokawa,
2010), and 180kD (Mitani, 2004). However, the protein shown in my analysis, running between
50 and 53kD, does not match any known isoforms.
Cross-reactivity occurs when an antibody recognizes an antigen that is common to more
than one protein and binds to the region in a protein other than the target (Mayer, 2010). The
Abcam antibody binds to residues 964-1013 on EVI1 (Abcam, n.d.). Scans of protein databases
show no sequence homology for this region except for other isotopes of EVI1 (European
Bioinformatics Institute, 2011; National Center for Biotechnology Information, 2011), indicating
that the protein detected is not the result of cross-reactivity of the antibody.
My results contradict the findings of Liu et al., (2006), Langabeer et al. (2006), and
Brooks et al. (1996), who have found elevated expression in several types of cancer. EVI1 has
been studied primarily in myeloid leukmias and documented as a dominant oncogene in this
form of cancer (Goyama & Kurokawa, 2010). Over-expression has also been documented in
HT-29 (Liu et al., 2006) and metastatic breast cancer (Patel et al., 2011). However, De Weer et
al. (2006) demonstrated that EVI1 expression is normal in acute lymphoblastic leukemia (ALL),
suggesting that is not a globally over-expressed protein. Of my tested lines, both CEM and U937
are derived from ALL.
Further blots are needed to confirm or refute the presence of the protein at 50-53kD.
Testing with a more specific antibody may reveal this as nonspecific binding; if not, further
testing is necessary to identify the protein. EVI1 is known to be expressed at very low
concentrations in normal cells (Soderholm et al. 1997), supporting my conclusion that the
blotting system was not sensitive enough to detect the protein. No conclusive study of EVI1
expression patterns in different types of cancers has been conducted. My study suggests that with
further testing, EVI1 or the unidentified protein found in my investigation may become a viable
broad-spectrum therapeutic target for cancer treatment.
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Inquiry Process
Student Inquiry and Research has taught me an immeasurable amount about
independence and perseverance. Looking back through my journal, I can trace the evolution
from depending almost completely on my advisor to dictate the next step to making most of my
own decisions about the process. I learned to research and reason through questions, issues, and
data in much more complicated ways than I have ever been exposed to in a science course. SIR
allowed me to delve much deeper into the area of my interest and provided the chance to
experience the true process of scientific research. In addition, I learned to reshape my questions
to more complex, nuanced inquiries. My lab skills evolved from rudimentary to somewhat
proficient at the tests required for my investigation, and at basic lab skills such as making
solutions.
SIR has drastically changed my concept of research. I came in with very little knowledge
about constructing a scientific investigation. Initially, I wanted to tackle much too broad of a
topic. I had no concept of the amount of time it takes to generate even a small, insignificant
result. Going through the process has revealed the less glamorous reality and given me a feel for
what can be accomplished in a year. It has demonstrated, to a small degree, the amount of work
that must be put into a project to obtain even a small result.
I chose an on-campus biology SIR due to difficulties finding an off-campus advisor.
Although this was not the path I planned to take, I have no regrets. Being on-campus allowed me
to build my lab skills and confidence with the research process, and to gain basic skills that I
may not have been exposed to in a larger laboratory. I was responsible for the entire experiment,
so I got the experience of working through each issue, and had the opportunity to work in the lab
each day instead of once a week. This process has confirmed my interest in biological research.
Although it is often difficult, I discovered that I truly enjoy the process of discovery, even when
the results are nonexistent or difficult.
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Figures and Tables
Table 1. Cell lines and morphologies.

Cell lines were obtained from ATCC.

Table 2. Viability and cell count at harvesting.

Suspended cell line viability and cell count were determined using a
hemacytometer. Molt-4, U937, CEM, and Kasumi-3 are suspended cell lines. HT29, MCF7, and M059K are adherent cell lines. Adherent cell line viability and total
cell count could not be measured conclusively.

Figure 1. Western blot for actin. All samples were 5uL. Actin runs at 43kD. Using
Gel Pro Analyzer, intensity of each band was measured and scaling factors were
determined. U937 was not used. Kasumi-3 displayed no protein expression (lane 4),
so it was not considered.
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Table 3. Scaling factors

Using Gel Pro Analyzer, the intensities of the bands from the
actin blot were compared to generate scaling factors. M059K
acted as the base.

Figure 2. Western blot for EVI1. All samples were 20uL. The most prominent band ran between 50 and
53kD. The intensity of this band for each cell line was measured using Gel Pro Analyzer and
normalized with the scaling factors. U937 was not included and Kasumi-3 showed no protein
expression.

Table 4. Raw and scaled pixel counts comparing florescent band intensity of the unidentified
protein at 50-53kD

The raw intensity measurements were determined using Gel Pro Analyzer. The scaled numbers show the
intensity of each band after normalization with the scaling factors.
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